Navigation Links
FDA Approves Eylea for Eye Disorder in Older People
Date:11/18/2011

SILVER SPRING, Md., Nov. 18, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

AMD gradually destroys a person's sharp, central vision. It affects the macula, the part of the eye that allows people to see fine detail needed to do daily tasks such as reading and driving.

There are two forms of AMD, a wet form and a dry form. The wet form of AMD includes the growth of abnormal blood vessels. The blood vessels can leak fluid into the central part of the retina, also known as the macula. When fluid leaks into the macula, the macula thickens and vision loss occurs. An early symptom of wet AMD occurs when straight lines appear to be wavy.

"Eylea is an important new treatment option for adults with wet AMD," said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. "It is a potentially blinding disease and the availability of new treatment options is important."

The safety and effectiveness of Eylea was evaluated in two clinical trials involving 2,412 adult patients. People in the study received either Eylea or Lucentis (ranibizumab injection). The primary endpoint in each study was a patient's clearness of vision (visual acuity) after one year of treatment.

Eylea is injected into the eye either every four weeks or every eight weeks by an ophthalmologist. The studies showed that Eylea was as effective as Lucentis in maintaining or improving visual acuity.  

The most commonly reported side effects in patients receiving Eylea included eye pain, blood at the injection site (conjunctival hemorrhage), the appearance of floating spots in a person's vision (vitreous floaters), clouding of the eye lens (cataract), and an increase in eye pressure.

Eylea should not be used in those who have an active eye infection or active ocular inflammation. Eylea has not been studied in pregnant women, so the treatment should be used only in pregnant women if the potential benefits of the treatment outweigh any potential risks. Age related macular degeneration does not occur in children and Eylea has not been studied in children.

Other FDA-approved treatment options for wet AMD include: Visudyne (verteporfin for injection) approved in 2000, Macugen (pegaptanib sodium injection) approved in 2004, and Lucentis (ranibizumab injection) approved in 2006.

Eylea is marketed by Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc.

For more information:

FDA: Spotlight on Drug Innovation – Update of FDA's novel drug approvals in 2011
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm254242.htm

NEI: Facts about Age-Related Macular Degeneration
http://www.nei.nih.gov/health/maculardegen/armd_facts.asp

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves First Supplemental Test for Chagas Disease
2. FDA Approves Erwinaze to Treat a Form of Leukemia
3. FDA Approves New York Blood Centers HEMACORD™ for Stem Cell Transplantation
4. FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer
5. FDA Approves Xarelto to Prevent Stroke in People With Common Type of Abnormal Heart Rhythm
6. FDA Approves U.S. Market Return for octagam® Following Octapharmas Implementation of Enhanced Safety Measures
7. FDA Approves First Artificial Aortic Heart Valve Placed Without Open-Heart Surgery
8. FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder
9. FDA Approves Onfi To Treat Severe Type of Seizures
10. FDA Approves Longer Duration Efficacy and Safety for EUFLEXXA®
11. FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... May 5, 2017   Provista , a proven leader ... 200,000 customers, today announced Jim Cunniff as the ... executive and business experience to Provista, including most recently serving ... California . He assumed his new role ... a great fit for Provista," says Jody Hatcher , ...
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Dymedix® Diagnostics, Inc., ... today it had completed the first phase of building a global distribution network. ... of world (ROW) authorized dealers specializing in polysomnography accessories. The company plans ...
(Date:5/23/2017)... ... 23, 2017 , ... PM360, the premier information resource for ... winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders • ... industry today. , Out of more than 500 submissions, 100 winners were selected ...
(Date:5/23/2017)... ... May 23, 2017 , ... The ... professionals, is pleased to announce the organization’s Certified Strength Coach credential has earned ... Strength Coach (CSC) program validates the competency of qualified candidates for jobs in ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... educating patients on peri-implantitis in Las Vegas, NV, and the importance ... custom gum disease consultation and leading care for peri-implantitis, with or without a ...
(Date:5/23/2017)... ... ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare applications during ... Health and IoT: Technology Innovators and Disruption , the workshop is part of ... and consulting firm specializing in emerging consumer technology products and services. , Orbita, ...
Breaking Medicine News(10 mins):